Baidu
map

EB病毒相关肿瘤的治疗:nanatinostat和valganciclovir联合方案获FDA孤儿药称号

2020-06-25 Allan MedSci原创

全世界约95%的成年人感染了EB病毒。感染通常是无症状的,病毒会在患者的整个生命周期中潜伏在小部分淋巴细胞中。在某些情况下,此类细胞可能经历恶性转化并成为淋巴瘤。

全世界约95%的成年人感染了EB病毒。感染通常是无症状的,病毒会在患者的整个生命周期中潜伏在小部分淋巴细胞中。在某些情况下,此类细胞可能经历恶性转化并成为淋巴瘤。除淋巴瘤外,EB病毒还与多种实体瘤相关,包括鼻咽癌和胃癌

专注于病毒相关恶性肿瘤的制药公司Viracta Therapeutics今日宣布,其nanatinostat和valganciclovir组合疗法已获得美国食品和药品监督管理局(FDA)的孤儿药称号,用以治疗EB病毒相关的T细胞淋巴瘤。nanatinostat和valganciclovir组合疗法先前曾获得过孤儿药称号,用于治疗移植后的淋巴增生性疾病、浆母细胞性淋巴瘤和血管免疫母细胞性T细胞淋巴瘤。

Nanatinostat(VRx-3996)是Viracta开发的一种口服组蛋白脱乙酰基酶(HDAC)抑制剂。 Nanatinostat对I类HDAC的特定同工型具有选择性,这是在EB病毒相关恶性肿瘤中诱导潜伏病毒基因的关键。

 

原始出处:

https://www.firstwordpharma.com/node/1735421?tsid=4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1053681, encodeId=3489105368153, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210528/a18cf35bdfab43d496bab2a120649fae/3b4d7ff9e9364c3bae15229ee94a1b36.jpg, createdBy=9ea25397643, createdName=妙医生, createdTime=Wed Sep 22 09:00:45 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971900, encodeId=1d1119e1900bc, content=<a href='/topic/show?id=f9c480e0860' target=_blank style='color:#2F92EE;'>#联合方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80708, encryptionId=f9c480e0860, topicName=联合方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Sun Mar 07 09:21:45 CST 2021, time=2021-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884414, encodeId=8b59188441486, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jan 05 01:21:45 CST 2021, time=2021-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933761, encodeId=ad271933e6170, content=<a href='/topic/show?id=71a81258504' target=_blank style='color:#2F92EE;'>#NCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12585, encryptionId=71a81258504, topicName=NCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ee7414, createdName=lanyan20020086, createdTime=Thu Jul 09 20:21:45 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633578, encodeId=796516335e858, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Thu Mar 25 10:21:45 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365238, encodeId=dfc1136523878, content=<a href='/topic/show?id=dfa045434e1' target=_blank style='color:#2F92EE;'>#孤儿药称号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45434, encryptionId=dfa045434e1, topicName=孤儿药称号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Sat Jun 27 09:21:45 CST 2020, time=2020-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379836, encodeId=db2213e983675, content=<a href='/topic/show?id=72fee303d6' target=_blank style='color:#2F92EE;'>#FDA孤儿药称号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7303, encryptionId=72fee303d6, topicName=FDA孤儿药称号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ebe466, createdName=mxj1971612, createdTime=Sat Jun 27 09:21:45 CST 2020, time=2020-06-27, status=1, ipAttribution=)]
    2021-09-22 妙医生

    受益匪浅

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1053681, encodeId=3489105368153, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210528/a18cf35bdfab43d496bab2a120649fae/3b4d7ff9e9364c3bae15229ee94a1b36.jpg, createdBy=9ea25397643, createdName=妙医生, createdTime=Wed Sep 22 09:00:45 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971900, encodeId=1d1119e1900bc, content=<a href='/topic/show?id=f9c480e0860' target=_blank style='color:#2F92EE;'>#联合方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80708, encryptionId=f9c480e0860, topicName=联合方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Sun Mar 07 09:21:45 CST 2021, time=2021-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884414, encodeId=8b59188441486, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jan 05 01:21:45 CST 2021, time=2021-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933761, encodeId=ad271933e6170, content=<a href='/topic/show?id=71a81258504' target=_blank style='color:#2F92EE;'>#NCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12585, encryptionId=71a81258504, topicName=NCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ee7414, createdName=lanyan20020086, createdTime=Thu Jul 09 20:21:45 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633578, encodeId=796516335e858, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Thu Mar 25 10:21:45 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365238, encodeId=dfc1136523878, content=<a href='/topic/show?id=dfa045434e1' target=_blank style='color:#2F92EE;'>#孤儿药称号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45434, encryptionId=dfa045434e1, topicName=孤儿药称号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Sat Jun 27 09:21:45 CST 2020, time=2020-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379836, encodeId=db2213e983675, content=<a href='/topic/show?id=72fee303d6' target=_blank style='color:#2F92EE;'>#FDA孤儿药称号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7303, encryptionId=72fee303d6, topicName=FDA孤儿药称号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ebe466, createdName=mxj1971612, createdTime=Sat Jun 27 09:21:45 CST 2020, time=2020-06-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1053681, encodeId=3489105368153, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210528/a18cf35bdfab43d496bab2a120649fae/3b4d7ff9e9364c3bae15229ee94a1b36.jpg, createdBy=9ea25397643, createdName=妙医生, createdTime=Wed Sep 22 09:00:45 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971900, encodeId=1d1119e1900bc, content=<a href='/topic/show?id=f9c480e0860' target=_blank style='color:#2F92EE;'>#联合方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80708, encryptionId=f9c480e0860, topicName=联合方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Sun Mar 07 09:21:45 CST 2021, time=2021-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884414, encodeId=8b59188441486, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jan 05 01:21:45 CST 2021, time=2021-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933761, encodeId=ad271933e6170, content=<a href='/topic/show?id=71a81258504' target=_blank style='color:#2F92EE;'>#NCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12585, encryptionId=71a81258504, topicName=NCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ee7414, createdName=lanyan20020086, createdTime=Thu Jul 09 20:21:45 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633578, encodeId=796516335e858, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Thu Mar 25 10:21:45 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365238, encodeId=dfc1136523878, content=<a href='/topic/show?id=dfa045434e1' target=_blank style='color:#2F92EE;'>#孤儿药称号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45434, encryptionId=dfa045434e1, topicName=孤儿药称号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Sat Jun 27 09:21:45 CST 2020, time=2020-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379836, encodeId=db2213e983675, content=<a href='/topic/show?id=72fee303d6' target=_blank style='color:#2F92EE;'>#FDA孤儿药称号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7303, encryptionId=72fee303d6, topicName=FDA孤儿药称号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ebe466, createdName=mxj1971612, createdTime=Sat Jun 27 09:21:45 CST 2020, time=2020-06-27, status=1, ipAttribution=)]
    2021-01-05 liye789132251
  4. [GetPortalCommentsPageByObjectIdResponse(id=1053681, encodeId=3489105368153, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210528/a18cf35bdfab43d496bab2a120649fae/3b4d7ff9e9364c3bae15229ee94a1b36.jpg, createdBy=9ea25397643, createdName=妙医生, createdTime=Wed Sep 22 09:00:45 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971900, encodeId=1d1119e1900bc, content=<a href='/topic/show?id=f9c480e0860' target=_blank style='color:#2F92EE;'>#联合方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80708, encryptionId=f9c480e0860, topicName=联合方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Sun Mar 07 09:21:45 CST 2021, time=2021-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884414, encodeId=8b59188441486, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jan 05 01:21:45 CST 2021, time=2021-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933761, encodeId=ad271933e6170, content=<a href='/topic/show?id=71a81258504' target=_blank style='color:#2F92EE;'>#NCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12585, encryptionId=71a81258504, topicName=NCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ee7414, createdName=lanyan20020086, createdTime=Thu Jul 09 20:21:45 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633578, encodeId=796516335e858, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Thu Mar 25 10:21:45 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365238, encodeId=dfc1136523878, content=<a href='/topic/show?id=dfa045434e1' target=_blank style='color:#2F92EE;'>#孤儿药称号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45434, encryptionId=dfa045434e1, topicName=孤儿药称号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Sat Jun 27 09:21:45 CST 2020, time=2020-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379836, encodeId=db2213e983675, content=<a href='/topic/show?id=72fee303d6' target=_blank style='color:#2F92EE;'>#FDA孤儿药称号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7303, encryptionId=72fee303d6, topicName=FDA孤儿药称号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ebe466, createdName=mxj1971612, createdTime=Sat Jun 27 09:21:45 CST 2020, time=2020-06-27, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1053681, encodeId=3489105368153, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210528/a18cf35bdfab43d496bab2a120649fae/3b4d7ff9e9364c3bae15229ee94a1b36.jpg, createdBy=9ea25397643, createdName=妙医生, createdTime=Wed Sep 22 09:00:45 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971900, encodeId=1d1119e1900bc, content=<a href='/topic/show?id=f9c480e0860' target=_blank style='color:#2F92EE;'>#联合方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80708, encryptionId=f9c480e0860, topicName=联合方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Sun Mar 07 09:21:45 CST 2021, time=2021-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884414, encodeId=8b59188441486, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jan 05 01:21:45 CST 2021, time=2021-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933761, encodeId=ad271933e6170, content=<a href='/topic/show?id=71a81258504' target=_blank style='color:#2F92EE;'>#NCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12585, encryptionId=71a81258504, topicName=NCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ee7414, createdName=lanyan20020086, createdTime=Thu Jul 09 20:21:45 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633578, encodeId=796516335e858, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Thu Mar 25 10:21:45 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365238, encodeId=dfc1136523878, content=<a href='/topic/show?id=dfa045434e1' target=_blank style='color:#2F92EE;'>#孤儿药称号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45434, encryptionId=dfa045434e1, topicName=孤儿药称号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Sat Jun 27 09:21:45 CST 2020, time=2020-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379836, encodeId=db2213e983675, content=<a href='/topic/show?id=72fee303d6' target=_blank style='color:#2F92EE;'>#FDA孤儿药称号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7303, encryptionId=72fee303d6, topicName=FDA孤儿药称号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ebe466, createdName=mxj1971612, createdTime=Sat Jun 27 09:21:45 CST 2020, time=2020-06-27, status=1, ipAttribution=)]
    2021-03-25 AspirantSuo
  6. [GetPortalCommentsPageByObjectIdResponse(id=1053681, encodeId=3489105368153, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210528/a18cf35bdfab43d496bab2a120649fae/3b4d7ff9e9364c3bae15229ee94a1b36.jpg, createdBy=9ea25397643, createdName=妙医生, createdTime=Wed Sep 22 09:00:45 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971900, encodeId=1d1119e1900bc, content=<a href='/topic/show?id=f9c480e0860' target=_blank style='color:#2F92EE;'>#联合方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80708, encryptionId=f9c480e0860, topicName=联合方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Sun Mar 07 09:21:45 CST 2021, time=2021-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884414, encodeId=8b59188441486, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jan 05 01:21:45 CST 2021, time=2021-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933761, encodeId=ad271933e6170, content=<a href='/topic/show?id=71a81258504' target=_blank style='color:#2F92EE;'>#NCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12585, encryptionId=71a81258504, topicName=NCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ee7414, createdName=lanyan20020086, createdTime=Thu Jul 09 20:21:45 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633578, encodeId=796516335e858, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Thu Mar 25 10:21:45 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365238, encodeId=dfc1136523878, content=<a href='/topic/show?id=dfa045434e1' target=_blank style='color:#2F92EE;'>#孤儿药称号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45434, encryptionId=dfa045434e1, topicName=孤儿药称号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Sat Jun 27 09:21:45 CST 2020, time=2020-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379836, encodeId=db2213e983675, content=<a href='/topic/show?id=72fee303d6' target=_blank style='color:#2F92EE;'>#FDA孤儿药称号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7303, encryptionId=72fee303d6, topicName=FDA孤儿药称号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ebe466, createdName=mxj1971612, createdTime=Sat Jun 27 09:21:45 CST 2020, time=2020-06-27, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1053681, encodeId=3489105368153, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210528/a18cf35bdfab43d496bab2a120649fae/3b4d7ff9e9364c3bae15229ee94a1b36.jpg, createdBy=9ea25397643, createdName=妙医生, createdTime=Wed Sep 22 09:00:45 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971900, encodeId=1d1119e1900bc, content=<a href='/topic/show?id=f9c480e0860' target=_blank style='color:#2F92EE;'>#联合方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80708, encryptionId=f9c480e0860, topicName=联合方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Sun Mar 07 09:21:45 CST 2021, time=2021-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884414, encodeId=8b59188441486, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jan 05 01:21:45 CST 2021, time=2021-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933761, encodeId=ad271933e6170, content=<a href='/topic/show?id=71a81258504' target=_blank style='color:#2F92EE;'>#NCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12585, encryptionId=71a81258504, topicName=NCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ee7414, createdName=lanyan20020086, createdTime=Thu Jul 09 20:21:45 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633578, encodeId=796516335e858, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Thu Mar 25 10:21:45 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365238, encodeId=dfc1136523878, content=<a href='/topic/show?id=dfa045434e1' target=_blank style='color:#2F92EE;'>#孤儿药称号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45434, encryptionId=dfa045434e1, topicName=孤儿药称号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Sat Jun 27 09:21:45 CST 2020, time=2020-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379836, encodeId=db2213e983675, content=<a href='/topic/show?id=72fee303d6' target=_blank style='color:#2F92EE;'>#FDA孤儿药称号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7303, encryptionId=72fee303d6, topicName=FDA孤儿药称号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ebe466, createdName=mxj1971612, createdTime=Sat Jun 27 09:21:45 CST 2020, time=2020-06-27, status=1, ipAttribution=)]

相关资讯

Viracta的HDAC抑制剂nanatinostat治疗EBV相关癌症,获得美国FDA的孤儿药物指定

Viracta Therapeutic宣布其2期候选药物nanatinostat与抗病毒药缬更昔洛韦联用,治疗移植后淋巴组织增生性疾病(PTLD)、浆细胞性淋巴瘤和血管免疫母细胞性T细胞淋巴瘤,获得了美国食品和药物管理局的Orphan药物指定。

Baidu
map
Baidu
map
Baidu
map